Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 9
2007 9
2008 21
2009 29
2010 31
2011 48
2012 74
2013 81
2014 71
2015 105
2016 122
2017 114
2018 102
2019 91
2020 88
2021 96
2022 79
2023 6
Text availability
Article attribute
Article type
Publication date

Search Results

1,035 results
Results by year
Filters applied: . Clear all
Page 1
Panobinostat (Farydak) for multiple myeloma.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2015 Aug 17;57(1475):e118-9. Med Lett Drugs Ther. 2015. PMID: 26262884 Review. No abstract available.
panobinostat (FARYDAK°). Multiple myeloma: too toxic!
[No authors listed] [No authors listed] Prescrire Int. 2016 Nov;25(176):257-259. Prescrire Int. 2016. PMID: 30715819 Review.
Panobinostat did not prolong survival. The median time to myeloma progression, relapse, or death was prolonged by about 3 months with the panobinostat-containing combination, and by a median of about 8 months in the subgroup of patients who had received at least two
Panobinostat did not prolong survival. The median time to myeloma progression, relapse, or death was prolonged by about 3 months with
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Dimopoulos MA, Richardson P, Lonial S. Dimopoulos MA, et al. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):460-473. doi: 10.1016/j.clml.2022.01.011. Epub 2022 Jan 19. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35148975 Free article. Review.
Data from recent clinical trials of immunomodulatory agents (pomalidomide), proteasome inhibitors (PIs; carfilzomib and ixazomib), monoclonal antibodies (elotuzumab, daratumumab, and isatuximab), and other novel therapies (including panobinostat-based therapy) are summariz …
Data from recent clinical trials of immunomodulatory agents (pomalidomide), proteasome inhibitors (PIs; carfilzomib and ixazomib), monoclona …
A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.
Wang Y, Huang J, Li B, Xue H, Tricot G, Hu L, Xu Z, Sun X, Chang S, Gao L, Tao Y, Xu H, Xie Y, Xiao W, Yu D, Kong Y, Chen G, Sun X, Lian F, Zhang N, Wu X, Mao Z, Zhan F, Zhu W, Shi J. Wang Y, et al. Cancer Res. 2020 Feb 1;80(3):536-548. doi: 10.1158/0008-5472.CAN-18-3987. Epub 2019 Nov 15. Cancer Res. 2020. PMID: 31732653
Moreover, combining DCZ0415 with the multiple myeloma chemotherapeutic melphalan or the HDAC inhibitor panobinostat induced synergistic antimyeloma activity. Therefore, targeting TRIP13 may be an effective therapeutic strategy for multiple myeloma, particularly refractory …
Moreover, combining DCZ0415 with the multiple myeloma chemotherapeutic melphalan or the HDAC inhibitor panobinostat induced synergist …
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Tzogani K, van Hennik P, Walsh I, De Graeff P, Folin A, Sjöberg J, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. Tzogani K, et al. Oncologist. 2018 May;23(5):631-636. doi: 10.1634/theoncologist.2017-0301. Epub 2017 Nov 30. Oncologist. 2018. PMID: 29192015 Free PMC article. Review.
On August 28, 2015, a marketing authorization valid through the European Union was issued for panobinostat, in combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two …
On August 28, 2015, a marketing authorization valid through the European Union was issued for panobinostat, in combination with borte …
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hütt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M. Grasso CS, et al. Nat Med. 2015 Jun;21(6):555-9. doi: 10.1038/nm.3855. Epub 2015 May 4. Nat Med. 2015. PMID: 25939062 Free PMC article.
We performed a chemical screen in patient-derived DIPG cultures along with RNA-seq analyses and integrated computational modeling to identify potentially effective therapeutic strategies. The multi-histone deacetylase inhibitor panobinostat demonstrated therapeutic efficac …
We performed a chemical screen in patient-derived DIPG cultures along with RNA-seq analyses and integrated computational modeling to identif …
Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML.
Salmon JM, Todorovski I, Stanley KL, Bruedigam C, Kearney CJ, Martelotto LG, Rossello F, Semple T, Arnau GM, Zethoven M, Bots M, Bjelosevic S, Cluse LA, Fraser PJ, Litalien V, Vidacs E, McArthur K, Matthews AY, Gressier E, de Weerd NA, Lichte J, Kelly MJ, Hogg SJ, Hertzog PJ, Kats LM, Vervoort SJ, De Carvalho DD, Scheu S, Bedoui S, Kile BT, Lane SW, Perkins AC, Wei AH, Dominguez PM, Johnstone RW. Salmon JM, et al. Cancer Discov. 2022 Jun 2;12(6):1560-1579. doi: 10.1158/2159-8290.CD-20-1145. Cancer Discov. 2022. PMID: 35311997 Free PMC article.
Plasmacytoid dendritic cells (pDC) produced type I IFN after panobinostat treatment, through transcriptional activation of IFN genes concomitant with increased H3K27 acetylation at these loci. Depletion of pDCs abrogated panobinostat-mediated induction of type I IFN …
Plasmacytoid dendritic cells (pDC) produced type I IFN after panobinostat treatment, through transcriptional activation of IFN genes …
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.
Lin GL, Wilson KM, Ceribelli M, Stanton BZ, Woo PJ, Kreimer S, Qin EY, Zhang X, Lennon J, Nagaraja S, Morris PJ, Quezada M, Gillespie SM, Duveau DY, Michalowski AM, Shinn P, Guha R, Ferrer M, Klumpp-Thomas C, Michael S, McKnight C, Minhas P, Itkin Z, Raabe EH, Chen L, Ghanem R, Geraghty AC, Ni L, Andreasson KI, Vitanza NA, Warren KE, Thomas CJ, Monje M. Lin GL, et al. Sci Transl Med. 2019 Nov 20;11(519):eaaw0064. doi: 10.1126/scitranslmed.aaw0064. Sci Transl Med. 2019. PMID: 31748226 Free PMC article.
In vivo testing in patient-derived xenograft models validated the combination of the multi-histone deacetylase (HDAC) inhibitor panobinostat and the proteasome inhibitor marizomib as a promising therapeutic approach. Transcriptional and metabolomic surveys revealed substan …
In vivo testing in patient-derived xenograft models validated the combination of the multi-histone deacetylase (HDAC) inhibitor panobinos
Pharmaceutical approval update.
Gohil K. Gohil K. P T. 2015 May;40(5):327-60. P T. 2015. PMID: 25987820 Free PMC article.
Filgrastim-sndz (Zarxio) to help prevent infections related to chemotherapy, dinutuximab (Unituxin) for high-risk pediatric neuroblastoma, and panobinostat (Farydak) for multiple myeloma....
Filgrastim-sndz (Zarxio) to help prevent infections related to chemotherapy, dinutuximab (Unituxin) for high-risk pediatric neuroblastoma, a …
1,035 results